Invention Grant
US08685934B2 Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
有权
在使用SGLT2抑制剂的其它抗糖尿病药物及其组合物的治疗中耐药的患者中极端胰岛素抵抗的方法
- Patent Title: Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
- Patent Title (中): 在使用SGLT2抑制剂的其它抗糖尿病药物及其组合物的治疗中耐药的患者中极端胰岛素抵抗的方法
-
Application No.: US13321103Application Date: 2010-05-26
-
Publication No.: US08685934B2Publication Date: 2014-04-01
- Inventor: Paul Strumph , Stephanie Moran , James List
- Applicant: Paul Strumph , Stephanie Moran , James List
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- International Application: PCT/US2010/036120 WO 20100526
- International Announcement: WO2010/138535 WO 20101202
- Main IPC: A61K31/70
- IPC: A61K31/70 ; A61K38/28 ; A61K31/33 ; A61K31/155
Abstract:
The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.
Public/Granted literature
Information query
